Pfizer Inc. (PFE) announced Wednesday positive top-line results from the Phase 3 JADE TEEN trial of Abrocitinib in adolescents with moderate-to-severe atopic dermatitis (AD). Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated.
from RTT - Biotech https://ift.tt/2YmRKhS
via IFTTT
No comments:
Post a Comment